Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22767939 | 0.84 | EPHX2 (0.43) | EPHX2ALDH1A1TDP1MAPTHPGD | |
| SCHEMBL16730498 | 0.79 | EPHX2 (0.56) | EPHX2ALOX15TSHRHSD17B10CYP1A2 | |
| SCHEMBL23223553 | 0.79 | EPHX2 (0.56) | EPHX2ALOX15TSHRHSD17B10CYP1A2 | |
| SCHEMBL22767940 | 0.79 | EPHX2 (0.56) | EPHX2ALOX15TSHRHSD17B10CYP1A2 | |
| SCHEMBL23136926 | 0.79 | EPHX2 (0.56) | EPHX2ALOX15TSHRHSD17B10CYP1A2 | |
| SCHEMBL17779345 | 0.79 | EPHX2 (0.56) | EPHX2ALOX15TSHRHSD17B10CYP1A2 | |
| SCHEMBL16730568 | 0.79 | EPHX2 (0.56) | EPHX2ALOX15TSHRHSD17B10CYP1A2 | |
| SCHEMBL17779380 | 0.79 | EPHX2 (0.56) | EPHX2ALOX15TSHRHSD17B10CYP1A2 | |
| SCHEMBL22767943 | 0.78 | EPHX2 (0.47) | EPHX2ALDH1A1TDP1MAPTHPGD | |
| SCHEMBL22767782 | 0.78 | EPHX2 (0.47) | EPHX2ALDH1A1TDP1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622942-B2 | Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622942-B2 | Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof | LIPA, LIPC, CES1 | EPHX2 324/4885L3MBTL1 698/4885CYP3A4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.